Disitamab vedotin targets HER2 on the cell surface; after internalization, MMAE is released and binds beta‑tubulin to disrupt microtubules and induce apoptosis (with a bystander effect). Expression of beta‑tubulin alone does not make cells directly targeted or killed by the drug.